COMP <GO>
UCAR vs TMO // DIVIDEND YIELD & FCF PAYOUT SAFETY
U Power Limited (Class A) (NASDAQ) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: UCAR 0
— TMO 9
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: TMO
LAST: $2.85 (-5.00%) • MKT CAP: $5.1M
dividend-safety
0.00%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
dividend-safety
0.24%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UCAR VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UCAR | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 36.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -18.50% | 9.30% | -27.80 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.40% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 17.40% | -77.40 | TMO | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 15.10% | -75.10 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -3.60% | 3.90% | -7.50 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 4.50 | -4.30 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 8/9 | -6.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.8 | 62.9 | -31.08 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 36.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.1M | $262.22B | -$262.21B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UCAR REV | TMO REV | UCAR GROSS % | TMO GROSS % | UCAR FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.9M | $44.56B | 36.3% | — | -$10.0M | $6.29B |
| FY 2024 | $6.1M | $42.88B | 23.6% | — | -$10.0M | $7.27B |
| FY 2023 | $2.8M | $42.86B | — | — | -$9.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UCAR // BETA —
TMO // BETA 0.94